Draupnir Bio ApS: Financial statements 2023
CVR: 38546880
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
Draupnir Bio ApS (CVR 38546880) has filed annual accounts for 2023. In 2023, the company reported a net result of DKK -41,166,000 compared with DKK -39,890,000 the year before. Equity in the 2023 report amounted to DKK 29,386,000. The solvency ratio was 81.2%. The company had 10 employees in the financial year.
- Profit/Loss
- DKK -41,166,000
- Equity
- DKK 29,386,000
- Total Assets
- DKK 36,192,000
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | - | -41.2 mio. | 29.4 mio. | 10 |
| 2022 | - | - | -39.9 mio. | 18.6 mio. | 13 |
| 2021 | - | - | -67 mio. | 53.5 mio. | - |
| 2020 | - | - | -60.6 mio. | 54.2 mio. | - |
| 2019 | - | -15.9 mio. | -15.2 mio. | 52 mio. | 2 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
Draupnir Bio ApS has published its annual report for 2022. The net result was DKK -39,890,000.
About Draupnir Bio ApS
Draupnir Bio ApS is a Danish company of the type Anpartsselskab based in Frederiksberg, founded in 2017. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Andrew Thomas Hotchkiss. The board consists of Eva-Lotta Coulter (chair), Emmanuelle Coutanceau, Ivan Burkov and Robert Andrew Donald Scott. The company's owners include Novo Holdings A/S, Coöperatieve Gilde Healthcare IV U.A. and Danmarks Eksport- og Investeringsfond. According to the 2025 annual report, the company had an average of 9 employees. Equity in the 2025 report amounted to DKK 15,256,000.